Proteins and Peptides

20 Oct 2016 Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus (HDV) Infection
17 Oct 2016 Ferring receives positive CHMP opinion for REKOVELLE® (follitropin delta)
16 Oct 2016 Abicipar Pegol PALM Study Phase 2 Data in Diabetic Macular Edema (DME) Presented at 2016 AAO Annual Meeting
13 Oct 2016 Allegro Ophthalmics Announces Positive Topline Results from DEL MAR Phase 2b Trial Evaluating Luminate® in Patients with Diabetic Macular Edema
13 Oct 2016 NeuroVive discontinues development of CicloMulsion for acute kidney injury
11 Oct 2016 Hansa Medical: First patient treated with IdeS in Phase II study in acquired Thrombotic Thrombocytopenic Purpura (TTP)
09 Oct 2016 Novo Nordisk receives Complete Response Letter in the US for faster-acting insulin aspart
09 Oct 2016 Molecular Partners Presents Data of MP0250 in an All-Comer Phase 1-Study in Solid Tumor Patients and Updates on Phase 2 Studies
07 Oct 2016 Coherus BioSciences Announces FDA Acceptance of 351(k) Biologics License Application to U.S. Food and Drug Administration for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
07 Oct 2016 BARDA Awards $37.6 million Contract to Sanofi to Supply Leukine® (sargramostim) for Potential Public Health Emergency
06 Oct 2016 Molecular Partners regains rights to multi-DARPin® drug candidate targeting IL-13 & IL-17 for pulmonary indications from Janssen
30 Sep 2016 CohBar Advances First-in-Class Mitochondria Based Therapeutic to IND-Enabling Activities
30 Sep 2016 Endo Pharmaceuticals Presents New Phase 2 Data Evaluating the Safety and Effectiveness of XIAFLEX® (Collagenase Clostridium Histolyticum) for Dupuytren's Disease Nodules
30 Sep 2016 Aurinia Announces That Voclosporin Achieves Primary and All Pre-Specified Secondary Endpoints in Its Phase IIb AURA-LV Study for Lupus Nephritis (LN)
27 Sep 2016 Amgen Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib) CLARION Study In Newly Diagnosed Multiple Myeloma Patients
26 Sep 2016 First Patient Dosed in CANbridge’s CAN-008 Phase I/II Trial in Newly-Diagnosed Glioblastoma Multiforme in Taiwan
26 Sep 2016 ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA) for Pancreatic Cancer
26 Sep 2016 Cinfa Biotech starts second clinical study of pegfilgrastim biosimilar candidate B12019
24 Sep 2016 Novo Nordisk submits application in the US for including data from the two SWITCH trials in Tresiba® label
22 Sep 2016 PharmaMar Submits MAA to EMA for Aplidin® for the Treatment of Multiple Myeloma
20 Sep 2016 Synthetic Biologics Announces Completion of Enrollment for Phase 2b Proof-of-Concept Clinical Trial for SYN-004 (ribaxamase) for the Prevention of Clostridium Difficile Infection, Antibiotic-Associated Diarrhea and the Emergence of Antibiotic-Resistant Or
20 Sep 2016 BioLineRx Announces Initiation of Phase 2a Trial of BL-8040 in Combination With KEYTRUDA® (pembrolizumab) for Treatment of Pancreatic Cancer
20 Sep 2016 Bexion Pharmaceuticals Doses First Patient in Phase I Trial of BXQ-350 For Patients with Advanced Solid Tumors at the University of Cincinnati Cancer Institute
19 Sep 2016 Stealth BioTherapeutics Reports Elamipretide Improved Skeletal Muscle Bioenergetics in the Elderly
17 Sep 2016 Phase III Combination Trial of BYDUREON and FARXIGA Shows Significant Blood Sugar Reduction in Patients with Type 2 Diabetes

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing